Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis

被引:3
|
作者
Topazian, Hillary M. [1 ,2 ]
Schmit, Nora [1 ]
Gerard-Ursin, Ines [1 ]
Charles, Giovanni D. [1 ]
Thompson, Hayley [1 ]
Ghani, Azra C. [1 ]
Winskill, Peter [1 ]
机构
[1] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, London, England
[2] Imperial Coll London, Fac Med, Sch Publ Hlth, Med Sch Bldg, St Marys Campus, Norfolk Pl, London W2 1PG, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
P; falciparum; Malaria; RTS; S; Malaria vaccine; Mathematical modelling; PLASMODIUM-FALCIPARUM MALARIA; INTERVENTIONS; AFRICA;
D O I
10.1016/j.vaccine.2023.04.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The World Health Organization has recommended a 4-dose schedule of the RTS,S/AS01 (RTS, S) vaccine for children in regions of moderate to high P. falciparum transmission. Faced with limited sup-ply and finite resources, global funders and domestic malaria control programs will need to examine the relative cost-effectiveness of RTS,S and identify target areas for vaccine implementation relative to scale-up of existing interventions. Methods: Using an individual-based mathematical model of P. falciparum, we modelled the cost-effectiveness of RTS,S across a range of settings in sub-Saharan Africa, incorporating various rainfall pat-terns, insecticide-treated net (ITN) use, treatment coverage, and parasite prevalence bands. We compare age-based and seasonal RTS,S administration to increasing ITN usage, switching to next generation ITNs in settings experiencing insecticide-resistance, and introduction of seasonal malaria chemoprevention (SMC) in areas of seasonal transmission. Results: For RTS,S to be the most cost-effective intervention option considered, the maximum cost per dose was less than $9.30 USD in 90.9% of scenarios. Nearly all (89.8%) values at or above $9.30 USD per dose were in settings with 60% established bed net use and / or with established SMC, and 76.3% were in the highest PfPR2-10 band modelled (40%). Addition of RTS,S to strategies involving 60% ITN use, increased ITN usage or a switch to PBO nets, and SMC, if eligible, still led to significant marginal case reductions, with a median of 2,653 (IQR: 1,741 to 3,966) cases averted per 100,000 people annually, and 82,270 (IQR: 54,034 to 123,105) cases averted per 100,000 fully vaccinated children (receiving at least three doses). Conclusions: Use of RTS,S results in reductions in malaria cases and deaths even when layered upon exist-ing interventions. When comparing relative cost-effectiveness, scale up of ITNs, introduction of SMC, and switching to new technology nets should be prioritized in eligible settings. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:3215 / 3223
页数:9
相关论文
共 50 条
  • [41] PARASITE GENETIC DIVERSITY AND PROTECTIVE EFFICACY IN A PHASE 3 TRIAL OF THE RTS,S/AS01 MALARIA VACCINE
    Neafsey, Daniel E.
    Juraska, Michal
    Bedford, Trevor
    Benkeser, David C.
    Valim, Clarissa
    Griggs, Allison D.
    Lievens, Marc
    Agbenyega, Tsiri
    Anderson, Scott
    Bruls, Myriam
    Connolly, Kristen M.
    D'Alessandro, Umberto
    Dobano, Carlota
    Grimsby, Jonna
    Hamel, Mary J.
    Leach, Amanda
    Lennon, Niall J.
    Moss, Eli L.
    Park, Daniel J.
    Pelle, Karell G.
    Robbins, Dana
    Russ, Carsten
    Ryan, Elizabeth M.
    Sogoloff, Brian
    Volkman, Sarah K.
    Yu, Qing
    Lapierre, Didier
    Birren, Bruce W.
    Gilbert, Peter B.
    Wirth, Dyann F.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (04): : 112 - 112
  • [42] Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report
    Merle, Corinne S.
    RTSS SMC working grp
    [J]. MALARIA JOURNAL, 2023, 22 (01)
  • [43] Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model
    Christopher J. Genito
    Katherine Brooks
    Alexis Smith
    Emma Ryan
    Kim Soto
    Yuanzhang Li
    Lucile Warter
    Sheetij Dutta
    [J]. npj Vaccines, 8
  • [44] Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report
    Corinne S. Merle
    [J]. Malaria Journal, 22
  • [45] Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status
    Gyaase, Stephaney
    Asante, Kwaku Poku
    Adeniji, Elisha
    Boahen, Owusu
    Cairns, Matthew
    Owusu-Agyei, Seth
    [J]. BMC PUBLIC HEALTH, 2021, 21 (01)
  • [46] Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model
    Genito, Christopher J. J.
    Brooks, Katherine
    Smith, Alexis
    Ryan, Emma
    Soto, Kim
    Li, Yuanzhang
    Warter, Lucile
    Dutta, Sheetij
    [J]. NPJ VACCINES, 2023, 8 (01)
  • [47] Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status
    Stephaney Gyaase
    Kwaku Poku Asante
    Elisha Adeniji
    Owusu Boahen
    Matthew Cairns
    Seth Owusu-Agyei
    [J]. BMC Public Health, 21
  • [48] Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine
    Christine Swysen
    Johan Vekemans
    Myriam Bruls
    Sunny Oyakhirome
    Chris Drakeley
    Peter Kremsner
    Brian Greenwood
    Opokua Ofori-Anyinam
    Brenda Okech
    Tonya Villafana
    Terrell Carter
    Barbara Savarese
    Adriano Duse
    Andrea Reijman
    Charlotte Ingram
    John Frean
    Bernhards Ogutu
    [J]. Malaria Journal, 10
  • [49] A PHASE IIIB COMPARATIVE TRIAL OF SEASONAL VACCINATION WITH THE MALARIA VACCINE RTS,S/AS01, SEASONAL MALARIA CHEMOPREVENTION AND OF THE TWO INTERVENTIONS COMBINED
    Chandramohan, Daniel
    Zongo, Issaka
    Sagara, Issaka
    Cairns, Matthew
    Yerbanga, Serge
    Diarra, Modibo
    Nikiema, Frederic
    Tapily, Amadou
    Sompougdou, Frederic
    Issiaka, Djibrilla
    Zoungrana, Charles
    Sanogo, Koualy
    Haro, Alassane
    Kaya, Mahamadou
    Sienou, Abdoul Aziz
    Traore, Seydou
    Mahamar, Almahamadou
    Thera, Ismaila
    Diarra, Kalifa
    Dolo, Amagana
    Kuepfer, Irene
    Snell, Paul
    Milligan, Paul
    Ockenhouse, Christian
    Ofori-Anyinam, Opokua
    Tinto, Halidou
    Djimde, Abdoulaye
    Ouedraogo, Jean-Bosco
    Dicko, Alassane
    Greenwood, Brian
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 410 - 410
  • [50] Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine
    Swysen, Christine
    Vekemans, Johan
    Bruls, Myriam
    Oyakhirome, Sunny
    Drakeley, Chris
    Kremsner, Peter
    Greenwood, Brian
    Ofori-Anyinam, Opokua
    Okech, Brenda
    Villafana, Tonya
    Carter, Terrell
    Savarese, Barbara
    Duse, Adriano
    Reijman, Andrea
    Ingram, Charlotte
    Frean, John
    Ogutu, Bernhards
    [J]. MALARIA JOURNAL, 2011, 10